CeriBell (NASDAQ:CBLL) CEO Xingjuan Chao Sells 39,000 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 39,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $19.90, for a total transaction of $776,100.00. Following the sale, the chief executive officer directly owned 802,317 shares in the company, valued at $15,966,108.30. The trade was a 4.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Xingjuan Chao also recently made the following trade(s):

• On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.33, for a total value of $714,870.00.
• On Thursday, May 21st, Xingjuan Chao sold 6,030 shares of CeriBell stock. The shares were sold at an average price of $18.00, for a total transaction of $108,540.00.
• On Tuesday, May 5th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $20.10, for a total transaction of $783,900.00.

CeriBell Trading Up 0.2%

Shares of CeriBell stock traded up $0.04 on Thursday, hitting $19.44. 34,641 shares of the company’s stock traded hands, compared to its average volume of 328,286. The company has a market capitalization of $737.71 million, a price-to-earnings ratio of -11.92 and a beta of 0.77. CeriBell, Inc. has a one year low of $10.85 and a one year high of $24.33. The company has a fifty day moving average of $18.69 and a two-hundred day moving average of $19.66. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The company had revenue of $26.49 million for the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. As a group, sell-side analysts expect that CeriBell, Inc. will post -1.69 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CBLL. Canaccord Genuity Group decreased their price target on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, CeriBell has a consensus rating of “Moderate Buy” and an average price target of $22.20.

Hedge Funds Weigh In On CeriBell

A number of large investors have recently modified their holdings of CBLL. Russell Investments Group Ltd. lifted its stake in shares of CeriBell by 41.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after buying an additional 854 shares in the last quarter. Sei Investments Co. raised its holdings in shares of CeriBell by 2.3% in the 1st quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after acquiring an additional 1,125 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares in the last quarter. Deutsche Bank AG boosted its stake in CeriBell by 1.7% during the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after purchasing an additional 1,393 shares during the last quarter. Finally, Strs Ohio acquired a new position in CeriBell during the 1st quarter valued at about $27,000.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.